Phase II Trial of Combined Modality Combretastatin A-4 Phosphate (CA4P)-Based Therapy for Patients With Newly Diagnosed Anaplastic Thyroid Cancer [Induction Chemotherapy With Doxorubicin/Cisplatin; Combined Modality Therapy With CA4P and Radiation; Followed by 2 Cycles of CA4P Consolidation]

Trial Profile

Phase II Trial of Combined Modality Combretastatin A-4 Phosphate (CA4P)-Based Therapy for Patients With Newly Diagnosed Anaplastic Thyroid Cancer [Induction Chemotherapy With Doxorubicin/Cisplatin; Combined Modality Therapy With CA4P and Radiation; Followed by 2 Cycles of CA4P Consolidation]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2010

At a glance

  • Drugs Cisplatin; Doxorubicin; Filgrastim; Fosbretabulin; Pegfilgrastim
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 16 Mar 2010 Additional lead trial investigator, Actual patient number (4) identified as reported by ClinicalTrials.gov.
    • 23 May 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top